The INOpulse vasodilator increased physical activity and helped maintain higher levels of exercise in people with PH-PF
The INOpulse vasodilator increased physical activity and helped maintain higher levels of exercise in people with pulmonary fibrosis (PH-PF)-associated pulmonary hypertension (PH). These are preliminary results of phase 2 trials.
INOpulse, developed by Bellerophon Therapeutics, is a form of inhaled nitric oxide, a powerful vasodilator – relaxes blood vessels, resulting in lower blood pressure – has shown an increase in physical performance of people with LH.
Phase 2, double-blind, placebo-controlled study INO-PF examines the effect of different INOpulse doses in three groups of people diagnosed with LF who are at risk of developing LH.
The results were presented during the 2019 Pulmonary Fibrosis Foundation Summit, held November 7-9 in San Antonio, Texas.